## Yuan-Kai Shi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6551898/publications.pdf

Version: 2024-02-01

51	4,880	23	51
papers	citations	h-index	g-index
52	52	52	5710 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 2014, 9, 154-162.	0.5	1,131
2	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589.	5.1	950
3	lcotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncology, The, 2013, 14, 953-961.	5.1	389
4	Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 1569.	3.4	388
5	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 867-875.	0.5	260
6	Tyrosine kinase inhibitors for solid tumors in the past 20Âyears (2001–2020). Journal of Hematology and Oncology, 2020, 13, 143.	6.9	226
7	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). British Journal of Cancer, 2018, 118, 654-661.	2.9	192
8	Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematology, the, 2019, 6, e12-e19.	2.2	176
9	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of Hematology and Oncology, 2017, 10, 69.	6.9	155
10	Results of PROFILE 1029, a Phase III Comparison ofÂFirst-Line Crizotinib versus Chemotherapy inÂEast Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1539-1548.	0.5	146
11	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219.	2.0	87
12	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respiratory Medicine,the, 2021, 9, 829-839.	5.2	66
13	Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research. 2019. 31, 152-161.	0.7	66
14	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. Journal of Thoracic Oncology, 2020, 15, 1015-1026.	0.5	58
15	Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer, 2015, 121, 3165-3181.	2.0	47
16	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. European Journal of Cancer, 2020, 130, 182-192.	1.3	46
17	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). Journal of Hematology and Oncology, 2021, 14, 12.	6.9	40
18	Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. Journal of Thoracic Oncology, 2011, 6, 1663-1669.	0.5	37

#	Article	IF	CITATIONS
19	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) Tj ETQq1	1 <sub>0.7</sub> 78431	l4.rgBT/O
20	Clinical response to apatinib monotherapy in advanced nonâ€small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 264-269.	0.7	31
21	Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. Clinical Cancer Research, 2020, 26, 6445-6452.	3.2	30
22	Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma. Oncologist, 2019, 24, e1251-e1261.	1.9	29
23	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. Theranostics, 2020, 10, 6399-6410.	4.6	26
24	High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. International Journal of Hematology, 2014, 99, 69-78.	0.7	21
25	A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy. Oncologist, 2020, 25, e833-e842.	1.9	19
26	A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 38.	6.9	18
27	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as firstâ€line treatment for Chinese patients with unresectable, metastatic, or recurrent nonâ€squamous non†smallâ€cell lung cancer: A multicenter, randomized, doubleâ€blinded, phase III trial. Cancer Communications, 2021, 41, 889-903.	3.7	16
28	Efficacy and safety of rhâ€endostatin (Endostar) combined with pemetrexed/cisplatin followed by rhâ€endostatin plus pemetrexed maintenance in nonâ€small cell lung cancer: A retrospective comparison with standard chemotherapy. Thoracic Cancer, 2018, 9, 1354-1360.	0.8	14
29	The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. The Lancet Regional Health - Western Pacific, 2021, 11, 100151.	1.3	13
30	Molecular profiling of Chinese <scp>Râ€CHOP</scp> treated <scp>DLBCL</scp> patients: Identifying a highâ€risk subgroup. International Journal of Cancer, 2020, 147, 2611-2620.	2.3	12
31	Circulating tumor cells ( <scp>CTCs</scp> )/circulating tumor endothelial cells ( <scp>CTECs</scp> ) and their subtypes in small cell lung cancer: Predictors for response and prognosis. Thoracic Cancer, 2021, 12, 2749-2757.	0.8	12
32	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged nonâ€"small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer, 2020, 150, 240-246.	0.9	10
33	Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study Journal of Clinical Oncology, 2020, 38, 9602-9602.	0.8	10
34	Râ€CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large Bâ€cell lymphoma. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 385-391.	0.7	9
35	The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005 $\hat{a}$ €"2020): A systematic review. The Lancet Regional Health - Western Pacific, 2021, 8, 100097.	1.3	9
36	The prognostic significance of tumor spread through air space in stage I lung adenocarcinoma. Thoracic Cancer, 2022, 13, 997-1005.	0.8	9

#	Article	IF	CITATIONS
37	A prognostic nomogram constructed for relapsed or refractory diffuse large Bâ€cell lymphoma patients. Asia-Pacific Journal of Clinical Oncology, 2019, , .	0.7	8
38	<p>Characteristics and Management of <em>TP53</em>-Mutated Diffuse Large B-Cell Lymphoma Patients</p> . Cancer Management and Research, 2020, Volume 12, 11515-11522.	0.9	8
39	<p>lcotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial</p> . Cancer Management and Research, 2020, Volume 12, 4633-4643.	0.9	8
40	Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens. Journal of Cancer, 2020, 11, 1516-1524.	1.2	8
41	Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget, 2016, 7, 72219-72228.	0.8	8
42	Highâ€throughput and multiâ€phases identification of autoantibodies in diagnosing earlyâ€stage breast cancer and subtypes. Cancer Science, 2022, 113, 770-783.	1.7	6
43	Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Investigational New Drugs, 2022, 40, 831-840.	1.2	6
44	Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases. Oncology Research, 2020, 28, 127-133.	0.6	5
45	Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2020, 10, 582567.	1.3	5
46	Event-free survival at 24Âmonths is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma. Annals of Hematology, 2020, 99, 2847-2857.	0.8	3
47	Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphoma. Future Oncology, 2021, 17, 1825-1838.	1.1	3
48	Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 3119-3129.	0.6	3
49	Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study. The Lancet Regional Health - Western Pacific, 2022, 23, 100452.	1.3	3
50	Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma. Future Oncology, 2022, 18, 1817-1827.	1.1	2
51	A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	0